BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 19669601)

  • 21. A novel MSH2 germline mutation in a Druze HNPCC family.
    Zidan J; Niessen RC; Laitman Y; Rozeveld D; Hofstra RM; Friedman E
    Fam Cancer; 2008; 7(2):135-9. PubMed ID: 17661183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extended microsatellite analysis in microsatellite stable, MSH2 and MLH1 mutation-negative HNPCC patients: genetic reclassification and correlation with clinical features.
    Schiemann U; Müller-Koch Y; Gross M; Daum J; Lohse P; Baretton G; Muders M; Mussack T; Kopp R; Holinski-Feder E
    Digestion; 2004; 69(3):166-76. PubMed ID: 15118395
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Screening for germline mutations of MLH1, MSH2, MSH6 and PMS2 genes in Slovenian colorectal cancer patients: implications for a population specific detection strategy of Lynch syndrome.
    Berginc G; Bracko M; Ravnik-Glavac M; Glavac D
    Fam Cancer; 2009; 8(4):421-9. PubMed ID: 19526325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers.
    van der Post RS; Kiemeney LA; Ligtenberg MJ; Witjes JA; Hulsbergen-van de Kaa CA; Bodmer D; Schaap L; Kets CM; van Krieken JH; Hoogerbrugge N
    J Med Genet; 2010 Jul; 47(7):464-70. PubMed ID: 20591884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of mismatch repair gene mutations in Turkish HNPCC patients.
    Tunca B; Pedroni M; Cecener G; Egeli U; Borsi E; Zorluoglu A; Di Gregorio C; Yilmazlar T; Yerci O; de Leon MP
    Fam Cancer; 2010 Sep; 9(3):365-76. PubMed ID: 20373145
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes.
    Domingo E; Niessen RC; Oliveira C; Alhopuro P; Moutinho C; Espín E; Armengol M; Sijmons RH; Kleibeuker JH; Seruca R; Aaltonen LA; Imai K; Yamamoto H; Schwartz S; Hofstra RM
    Oncogene; 2005 Jun; 24(24):3995-8. PubMed ID: 15782118
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical findings with implications for genetic testing in families with clustering of colorectal cancer.
    Wijnen JT; Vasen HF; Khan PM; Zwinderman AH; van der Klift H; Mulder A; Tops C; Møller P; Fodde R
    N Engl J Med; 1998 Aug; 339(8):511-8. PubMed ID: 9709044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of new founder Alu-mediated rearrangements in MSH2 gene associated with a Lynch syndrome phenotype.
    Pérez-Cabornero L; Borrás Flores E; Infante Sanz M; Velasco Sampedro E; Acedo Becares A; Lastra Aras E; Cuevas González J; Pineda Riu M; Ramón y Cajal Asensio T; Capellá Munar G; Miner Pino C; Durán Domínguez M
    Cancer Prev Res (Phila); 2011 Oct; 4(10):1546-55. PubMed ID: 21778331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of hereditary nonpolyposis colorectal cancer-related tumors displaying low microsatellite instability with MSH6 germline mutations.
    Wu Y; Berends MJ; Mensink RG; Kempinga C; Sijmons RH; van Der Zee AG; Hollema H; Kleibeuker JH; Buys CH; Hofstra RM
    Am J Hum Genet; 1999 Nov; 65(5):1291-8. PubMed ID: 10521294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluating the performance of clinical criteria for predicting mismatch repair gene mutations in Lynch syndrome: a comprehensive analysis of 3,671 families.
    Steinke V; Holzapfel S; Loeffler M; Holinski-Feder E; Morak M; Schackert HK; Görgens H; Pox C; Royer-Pokora B; von Knebel-Doeberitz M; Büttner R; Propping P; Engel C;
    Int J Cancer; 2014 Jul; 135(1):69-77. PubMed ID: 24493211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The spectrum of Lynch syndrome-associated germ-line mutations in Russia.
    Yanus GA; Akhapkina TA; Iyevleva AG; Kornilov AV; Suspitsin EN; Kuligina ES; Ivantsov AO; Aleksakhina SN; Sokolova TN; Sokolenko AP; Togo AV; Imyanitov EN
    Eur J Med Genet; 2020 Mar; 63(3):103753. PubMed ID: 31491536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Two mismatch repair gene mutations found in a colon cancer patient--which one is pathogenic?
    Kariola R; Otway R; Lönnqvist KE; Raevaara TE; Macrae F; Vos YJ; Kohonen-Corish M; Hofstra RM; Nyström-Lahti M
    Hum Genet; 2003 Feb; 112(2):105-9. PubMed ID: 12522549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hereditary nonpolyposis colorectal cancer: diagnostic strategies and their implications.
    Bonis PA; Trikalinos TA; Chung M; Chew P; Ip S; DeVine DA; Lau J
    Evid Rep Technol Assess (Full Rep); 2007 May; (150):1-180. PubMed ID: 17764220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heterozygous mutations in PMS2 cause hereditary nonpolyposis colorectal carcinoma (Lynch syndrome).
    Hendriks YM; Jagmohan-Changur S; van der Klift HM; Morreau H; van Puijenbroek M; Tops C; van Os T; Wagner A; Ausems MG; Gomez E; Breuning MH; Bröcker-Vriends AH; Vasen HF; Wijnen JT
    Gastroenterology; 2006 Feb; 130(2):312-22. PubMed ID: 16472587
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hereditary nonpolyposis colorectal cancer in endometrial cancer patients.
    Yoon SN; Ku JL; Shin YK; Kim KH; Choi JS; Jang EJ; Park HC; Kim DW; Kim MA; Kim WH; Lee TS; Kim JW; Park NH; Song YS; Kang SB; Lee HP; Jeong SY; Park JG
    Int J Cancer; 2008 Mar; 122(5):1077-81. PubMed ID: 17973265
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The founder mutation MSH2*1906G-->C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population.
    Foulkes WD; Thiffault I; Gruber SB; Horwitz M; Hamel N; Lee C; Shia J; Markowitz A; Figer A; Friedman E; Farber D; Greenwood CM; Bonner JD; Nafa K; Walsh T; Marcus V; Tomsho L; Gebert J; Macrae FA; Gaff CL; Paillerets BB; Gregersen PK; Weitzel JN; Gordon PH; MacNamara E; King MC; Hampel H; De La Chapelle A; Boyd J; Offit K; Rennert G; Chong G; Ellis NA
    Am J Hum Genet; 2002 Dec; 71(6):1395-412. PubMed ID: 12454801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nine novel pathogenic germline mutations in MLH1, MSH2, MSH6 and PMS2 in families with Lynch syndrome.
    Rahner N; Friedrichs N; Wehner M; Steinke V; Aretz S; Friedl W; Buettner R; Mangold E; Propping P; Walldorf C
    Acta Oncol; 2007; 46(6):763-9. PubMed ID: 17653898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genomic rearrangements in MSH2, MLH1 or MSH6 are rare in HNPCC patients carrying point mutations.
    Pistorius S; Görgens H; Plaschke J; Hoehl R; Krüger S; Engel C; Saeger HD; Schackert HK
    Cancer Lett; 2007 Apr; 248(1):89-95. PubMed ID: 16837128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Value of MLH1 and MSH2 mutations in the appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas.
    Ponti G; Losi L; Pedroni M; Lucci-Cordisco E; Di Gregorio C; Pellacani G; Seidenari S
    J Invest Dermatol; 2006 Oct; 126(10):2302-7. PubMed ID: 16826164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hereditary colorectal cancer in the general population: from cancer registration to molecular diagnosis.
    de Leon MP; Pedroni M; Benatti P; Percesepe A; Di Gregorio C; Foroni M; Rossi G; Genuardi M; Neri G; Leonardi F; Viel A; Capozzi E; Boiocchi M; Roncucci L
    Gut; 1999 Jul; 45(1):32-8. PubMed ID: 10369701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.